Australia, April 8 -- Constellation Pharmaceuticals Inc., owns the trademark (2516066) for 'PELLMOFY' till Sept. 30, 2034.
Status: protected:
Registered/protected
Class: 5 [Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules; small molecule compounds for medical use and drug delivery; small molecule pharmaceuticals for the treatment of diseases and conditions; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders; antibodies sold as a component ingredient of pharmaceuticals; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis; clinical medical reagents; biological preparations for medical purposes; pharmaceutical and veterinary preparations, agents and substances.]
Type of Mark: Word
Date of Acceptance: Jan. 29
Registration Advertised: April 7
For further details contact Davies Collison Cave Pty. Ltd. and Keith Toms, Esq. McCarter & English LLP .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2516066.
Disclaimer: Curated by HT Syndication.
